Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences, Germany s Merck Group in Pharmacogenomics Alliance

NEW YORK, Sept. 4-The California company DNA Sciences said today that it had struck a pharmacogenomics research collaboration with Germany's Merck Group.

 

Researchers from the two companies will work together to identify DNA variants associated with different drug responses. The team will then analyze allele frequencies of those genes in three separate ethnic groups.

 

Merck Group (Merck KGaA) is an international pharmaceutical and chemical manufacturer based in Darmstadt, Germany.

 

DNA Sciences, based in Fremont, Calif., develops and markets DNA-based diagnostics and pharmacogenomic techniques.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.